NCT01430572 2023-06-06
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
8 trialsNCT02303028 2022-06-28
TOPAZ
The Hospital for Sick Children
Phase 1/2 Completed
NCT02450136 2022-06-15
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT02691767 2022-06-15
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT01713972 2019-03-01
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00732420 2017-11-13
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01485042 2017-09-01
PATH
Duke University
Phase 1 Completed
NCT01072890 2012-03-28
Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
University of California, Davis
Phase 1 Completed